Please login to the form below

Not currently logged in
Email:
Password:

New Molecular Entities

This page shows the latest New Molecular Entities news and features for those working in and with pharma, biotech and healthcare.

Pharma is ‘getting lower returns on R&D’

Pharma is ‘getting lower returns on R&D’

Deloitte also welcomes an increase in the number of approvals of new molecular entities, orphan drugs and break/fast-tracked therapies which its says “leads us to present an overall optimistic ... with new ways of engaging patients in clinical trials

Latest news

  • After some big setbacks, Sanofi talks up its R&D portfolio After some big setbacks, Sanofi talks up its R&D portfolio

    Sanofi said in a preview of the event this morning that its pipeline currently has 71 projects, including 37 new molecular entities and novel vaccines, with nine potential marketing applications in

  • ICON boosts leadership teams ICON boosts leadership teams

    Pharmaceutical service provider ICON has boosted its scientific operations, medical imaging and real world evidence leadership teams with three new senior appointments. ... Most recently, Dr McCracken led the Imaging Centre of Excellence at Eisai, having

  • The UK's new Cancer Drugs Fund The UK's new Cancer Drugs Fund

    The new CDF started operating at the end of July, with four new cancer drugs made available under the scheme. ... We have made five cancer medicines available to UK patients in the last three years and have 70 new molecular entities in our pipeline but,

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    Therefore new medicines are needed for patients.". In a phase II trial, the combination of doxorubicin plus Lartruvo was able to improve survival time by almost 12 months compared to doxorubicin ... The drug is one of 20 new molecular entities (NMEs) the

  • Global pharma market forecast to reach $1.12tr by 2022 Global pharma market forecast to reach $1.12tr by 2022

    sales, according to a new report. ... EvaluatePharma expects new products to drive this growth, with the upward trajectory of approvals for new molecular entities (NMEs) that saw 50 NMEs approved in 2014 and 56 in 2015 showing

More from news
Approximately 2 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer); ... The company generates

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    Despite the new schemes, healthcare in China is still considered expensive, with out-ofpocket payments commonly high. ... Conversely, however, Brazil's uptake of New Molecular Entities (NMEs) between 2006-2010 was the highest of the BRIC nations – with

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    Chancellor Merkel has proposed a new system of financial regulation within the EU. ... Source: EFPIA, 2009. According to Vfa in 2010 only 26 new molecular entities were launched in the German market, compared to 36 in 2009.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics